Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2017) Bart L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations

(2017) Erden Atilla et al.   Balkan Medical Journal

Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia

(2016) Jun Aoki et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis

(2016) Armin Rashidi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years)

(2016) M Pohlen et al.   BONE MARROW TRANSPLANTATION

Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly

(2016) Heidi D. Klepin   CLINICS IN GERIATRIC MEDICINE

Donor and recipient sex in allogeneic stem cell transplantation: what really matters

(2016) H. T. Kim et al.   HAEMATOLOGICA

Donor and recipient sex in allogeneic stem cell transplantation: what really matters

(2016) H. T. Kim et al.   HAEMATOLOGICA

Kinetics of peripheral blood chimerism for surveillance of patients with leukemia and chronic myeloid malignancies after reduced-intensity conditioning allogeneic hematopoietic SCT

(2015) L Eggimann et al.   BONE MARROW TRANSPLANTATION

Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival

(2014) John Koreth et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

(2014) Elias J. Jabbour et al.   CANCER

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

(2011) S M Luger et al.   BONE MARROW TRANSPLANTATION